Premium
Recombinant bispecific antibodies for the targeting of adenoviruses to CEA‐expressing tumour cells: a comparative analysis of bacterially expressed single‐chain diabody and tandem scFv
Author(s) -
Korn Tina,
Nettelbeck Dirk M.,
Völkel Tina,
Müller Rolf,
Kontermann Roland E.
Publication year - 2004
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.555
Subject(s) - recombinant dna , microbiology and biotechnology , antibody , chemistry , phage display , antigen , transduction (biophysics) , periplasmic space , in vitro , bispecific antibody , cell culture , linker , monoclonal antibody , biology , escherichia coli , biochemistry , immunology , gene , genetics , computer science , operating system
We have generated two distinct recombinant bispecific antibody molecules for the retargeting of adenoviral vectors to CEA‐expressing tumour cells. These antibody molecules were produced by combining the antigen‐binding sites of a neutralising anti‐fibre knob scFv (S11) and an anti‐CEA antibody either in a single‐chain diabody format (scDb CEA‐S11) or a tandem scFv format (taFv CEA‐S11). In order to facilitate expression of taFv CEA‐S11 in bacteria we selected from a phage display library taFv molecules with an optimised linker that connects the two scFv fragments. ScDb CEA‐S11 and taFv CEA‐S11 were expressed and purified in soluble form from the bacterial periplasm with yields of approximately 100 µg per litre of bacterial culture. In vitro , both bispecific molecules mediated selective and enhanced transduction of CEA‐expressing tumour cells by recombinant adenoviruses. These assays did not reveal any differences in efficiency of adenoviral transduction by the two antibody formats. However, compared with taFv CEA‐S11, scDb CEA‐S11 exhibited a 2‐ to 3‐fold increased stability in human plasma at 37 °C. In summary, we could demonstrate that both formats are suitable for adenovirus targeting to tumour cells with similar biological activity in vitro . Copyright © 2004 John Wiley & Sons, Ltd.